Rfgene

About Rfgene

Founded in 2009 and headquartered in Hangzhou, China, Rfgene is a private AgTech and Life Sciences company specializing in agricultural biotechnology. The company's core activities include the research and development of functional gene mining, transformation body creation, and screening processes to cultivate new generations of crop varieties. Rfgene is also involved in both domestic and international safety evaluations for genetically modified crops.

The company's business model is centered on the development and commercialization of advanced agricultural technologies. This includes creating genetically modified seeds with desirable traits, such as higher yields or resistance to specific environmental conditions. Rfgene's recent patent activity includes a pending patent for a transgenic soybean event and its detection method, filed in 2022, indicating its ongoing research in crop improvement. The firm's revenue is generated through the sale of these proprietary bio-engineered products and potentially through licensing its technology to other seed companies.

Rfgene is backed by private equity and has attracted investments from notable firms such as Boyu Capital, CITIC Agriculture, and Yuan Longping High-Tech Agriculture. The company has also engaged in strategic investments, including a corporate deal with Goldoctor Seed in March 2023, to expand its market presence and technological capabilities.